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Ifosfamide-induced Fanconi syndrome is a rare complication that typically occurs 
in young patients due to a cumulative dose of ifosfamide > 40–60 g/m2, a reduc-
tion in kidney mass, or concurrent cisplatin treatment. It is usually characterized 
by severe and fatal progression accompanied by type II proximal renal tubular 
dysfunction, as evidenced by glycosuria, proteinuria, electrolyte loss, and met-
abolic acidosis. Diabetes insipidus is also a rare complication of ifosfamide-in-
duced renal disease. We herein describe a case involving a 61-year-old man who 
developed ifosfamide-induced Fanconi syndrome accompanied by diabetes insip-
idus only a few days after the first round of chemotherapy. He had no known risk 
factors. In addition, we briefly review the mechanisms and possible therapeutic 
options for this condition based on other cases in the literature. Patients who 
receive ifosfamide must be closely monitored for renal impairment to avoid this 
rare but fatal complication.
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INTRODUCTION
Ifosfamide is an alkylating agent with remarkable ac-
tivity against a wide range of tumors. Ifosfamide-in-
duced nephrotoxicity was first described in 1972 and is 
characterized by glomerulopathy, diabetes insipidus, 
and proximal tubulopathy [1]. Fanconi syndrome is a 
rare disease characterized by type II proximal renal tu-
bular dysfunction associated with the urinary loss of 
phosphate, bicarbonate, potassium, glucose, amino ac-
ids, and low-molecular-weight proteins. Ifosfamide-in-
duced Fanconi syndrome develops in children. Only a 
few cases have been reported in adults, who generally 
have risk factors such as a cumulative ifosfamide dose 
> 40–60 g/m2 [2], a reduction in kidney mass [3], or con-
current cisplatin treatment [3]. Diabetes insipidus is 
another rare complication of ifosfamide-induced renal 
disease. We herein report a case of ifosfamide-induced 
Fanconi syndrome with an onset of diabetes insipidus 
only a few days after the first ifosfamide exposure.
CASE REPORT
A 61-year-old Russian man was admitted to the clinic 
for evaluation of a 5-cm axillary mass that had invaded 
the adjacent bony structures. He was diagnosed with 
inflammatory malignant fibrous histiocytoma. Neoad-
juvant chemotherapy with adriamycin (25 mg/m2) and 
ifosfamide (2.5 g/m2) was administered on days 1 to 3 
following mesna prophylaxis. On day 3 of chemothera-
py, the patient showed general weakness, polyuria, and 
dehydration. Laboratory findings included hyperna-
tremia (serum sodium, 150 mmol/L), hypokalemia (se-
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rum potassium, 1.7 mmol/L), hypercalcemia (serum 
calcium, 10.6 mg/dL), and hypophosphatemia (serum 
phosphate, 2.1 mg/dL). The combination of hyperna-
tremia, hyperosmolarity, polydipsia, and polyuria were 
consistent with nephrogenic diabetes insipidus (Table 
1). The patient was thus treated with electrolyte replace-
ment and dichlozid. However, his electrolyte imbal-
ances were aggravated by this treatment, and his men-
tal status deteriorated to a stupor. Six days after 
chemotherapy, his serum blood urea nitrogen and cre-
atinine levels increased to 49.5 mg/dL (normal, 5.0 to 
25.0) and 1.81 mg/dL (normal, 0.5 to 1.4), respectively. A 
24-hour urinalysis revealed urinary loss of glucose, 
amino acids, uric acid, and potassium. The presence of 
these multiple defects in renal proximal tubular reab-
sorption, including glycosuria, hypophosphatemia, 
and proteinuria, were suggestive of Fanconi syndrome 
(Table 1). Treatment of isotonic saline with electrolyte 
replacement was maintained. However, the electrolyte 
imbalance was not corrected, and the metabolic acido-
sis was aggravated by this treatment. Nine days after 
chemotherapy, the patient died of uncorrected meta-
bolic acidosis.
DISCUSSION
Ifosfamide-induced Fanconi syndrome has been re-
ported in several patients with risk factors such as a cu-
mulative dose > 40–60 g/m2 ifosfamide [2], young age 
[4], reduction in kidney mass [3], or application of a con-
current nephrotoxic agent such as cisplatin [3]. One 
Table 1. Laboratory findings between baseline and day 3 after ifosfamide treatment
Parameter Baseline Day 3 after ifosfamide Normal value
Serum
Sodium, mEq/L 136 165  135.0–145.0
Potassium, mEq/L 3.8 2.2  3.5–5.5
Bicarbonate, mEq/L 23 18 24–30
Chloride, mEq/L 98 128  98–110
Blood urea nitrogen, mg/dL 16.8 50.2  5.0–25.0
Creatinine, mg/dL   0.65    1.81 0.50–1.40
Calcium, mg/dL 9.9 10.6  8.5–10.5
Inorganic phosphorus, mg/dL 2.6 2.1  2.5–4.5
Total protein, g/L  5.6 4.7 6.0–8.0
Albumin, g/L 2.2 2.2  3.3–5.3
Uric acid, µmol/L 3.3 3.7 2.5–7.5
Osmolality, mOsm/kg - 347 289.0–308.0
Glucose, mg/dL 58 119   70–110
Urine 
Urinary volume, mL/24 hr 1,680 6,020     500–2,000
Specific gravity   1.01   1.01 1.00–1.03
β2-Microglobulin, mg/L -  41.6   0.0–0.25
Protein, mg/24 hr -  3,244.8    0.0–150.0
Albumin, mg/24 hr - 413.0   0.0–30.0
Glucose, mg/24 hr - 2,227.4    500–1,500
Sodium, mmol/24 hr - 270.9    40.0–220.0
Potassium, mmol/24 hr -  171.6    25–120
Uric acid, mg/24 hr - 1,198 250–750
Creatinine clearance, mg/24 hr - 1,060    800–1,800
Osmolality, mOsm/kg - 283       50–1,200
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case report described a 48-year-old woman with Fan-
coni syndrome and nephrogenic diabetes insipidus af-
ter treatment with a cumulative dose of 41 g/m2 ifosfa-
mide [5]. Her renal function returned to normal after 
20 days. Another case report described a 54-year-old 
man with Fanconi syndrome and nephrogenic diabetes 
insipidus after ifosfamide treatment (total cumulative 
dose, 44 g/m2) [6]. Compared with these previous re-
ports, our case is novel in several ways. First, the total 
dosage of ifosfamide was only 7.5 g/m2 in our patient. 
Second, our patient had no known risk factors for ifos-
famide-induced nephropathy, such as young age, a 
high total ifosfamide dose, prior or concurrent cispla-
tin treatment, pre-existing renal impairment, ne-
phrectomy, or tumor infiltration.
The pathophysiology of ifosfamide-induced Fanconi 
syndrome is unclear. Previous theories have pointed to 
chloroacetaldehyde as the causal metabolite [7]. Ifosfa-
mide is metabolized into chloroacetaldehyde, which 
accumulates in the proximal tubular cells and results 
in nephrotoxicity. In addition, chloroacetaldehyde has 
been shown to decrease antioxidant glutathione (GSH) 
and adenosine triphosphate (ATP) levels while inhibit-
ing the activity of NA+/K+-ATPase, which is a V-ATPase. 
This process is associated with reduced endocytosis 
and intracellular processing of proteins [8]. Another 
explanation for the nephrotoxicity is possible depletion 
of intracellular GSH levels. GSH is the major intracel-
lular scavenger of oxygen radicals and an active metab-
olite of ifosfamide. 4-Hydroxyifosfamide has been re-
ported to deplete intracellular GSH levels [8].
Renal Fanconi syndrome is a serious condition, and 
there is no established treatment with the exception of 
hydration and correction of electrolyte imbalance. Pre-
liminary animal models have shown that the addition 
of antioxidants, such as N-acetylcysteine, resveratrol, 
melatonin, L-carnitine, and thymoquinone, to ifosfa-
mide treatment may have promising results, but fur-
ther research is necessary before these drugs are used 
as therapeutic options [9,10]. Therefore, early detection 
of potential tubular dysfunction is necessary. Fanconi 
syndrome is a disease characterized by type II proxi-
mal renal tubular dysfunction consistent with urinary 
loss of phosphate, bicarbonate, potassium, glucose, 
amino acids, and low-molecular-weight proteins. 
Therefore, serum electrolytes, urinary excretion of 
low-molecular-weight proteins, urinary electrolytes, 
and renal concentration capacity should be monitored 
regularly during and after ifosfamide chemotherapy.
In summary, we have reported a case involving a 
61-year-old man who developed Fanconi syndrome 
with nephrogenic diabetes insipidus after ifosfamide 
chemotherapy. The mechanisms of ifosfamide-in-
duced nephrotoxicity are not clear, and treatments are 
limited. Close monitoring is needed during ifosfamide 
treatment.
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